ADMA Biologics, Inc. ADMA
12.67 USD -0.12 (-0.94%)
At closeNov 11, 2026, 6:17 AM EST
12.71 +0.04 +0.32%
Pre-market · Nov 11, 6:17 AM ET
12.55 Day range 12.95
7.21 52-week range 20.46
- YTD
- -30.54%
- 1 year
- -13.87%
News
zacks.com Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a…
zacks.com Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
benzinga.com ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
benzinga.com Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday U.S. stocks were mixed as Nasdaq fell over 3%, while Motorola Solutions and other companies surged on strong earnings and raised guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
benzinga.com Why AppLovin Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket AppLovin surged 16.5% premarket after Q3 revenue and EPS beat estimates and Q4 guidance topped forecasts; MNTN plunged 42.3% on weak results.
benzinga.com Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13 Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.
benzinga.com ADMA Biologics (ADMA) Shares Jump 28% After-Hours: Here’s Why ADMA Biologics shares surge after Q3 earnings growth as the company raises 2026 profit guidance.
seekingalpha.com ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
zacks.com Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
marketbeat.com ADMA Biologics Q3 Earnings Call Highlights ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive…
benzinga.com ADMA Biologics Q3 2026 Earnings Call Transcript ADMA Biologics (NASDAQ:ADMA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is a 43.75 percent increase over earnings of $0.16…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
globenewswire.com ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update 3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37%…